4//SEC Filing
MacDougall Ann L. 4
Accession 0001385508-21-000046
CIK 0001385508other
Filed
Mar 16, 8:00 PM ET
Accepted
Mar 17, 4:53 PM ET
Size
19.9 KB
Accession
0001385508-21-000046
Insider Transaction Report
Form 4
MacDougall Ann L.
Director
Transactions
- Sale
Common Stock
2021-03-17$11.07/sh−6,606$73,128→ 20,838 total - Exercise/Conversion
Stock Option (right to buy)
2021-03-16$10.00/sh−2,231$22,310→ 7,620 totalExercise: $10.00Exp: 2021-05-16→ Common Stock (2,231 underlying) - Exercise/Conversion
Common Stock
2021-03-15$10.00/sh+6,483$64,830→ 25,483 total - Sale
Common Stock
2021-03-15$11.63/sh−5,600$65,128→ 19,883 total - Exercise/Conversion
Common Stock
2021-03-17$10.00/sh+7,279$72,790→ 27,444 total - Exercise/Conversion
Stock Option (right to buy)
2021-03-17$10.00/sh−7,279$72,790→ 341 totalExercise: $10.00Exp: 2021-05-16→ Common Stock (7,279 underlying) - Exercise/Conversion
Common Stock
2021-03-16$10.00/sh+2,231$22,310→ 22,114 total - Sale
Common Stock
2021-03-16$11.50/sh−1,949$22,414→ 20,165 total - Exercise/Conversion
Stock Option (right to buy)
2021-03-15$10.00/sh−6,483$64,830→ 9,851 totalExercise: $10.00Exp: 2021-05-16→ Common Stock (6,483 underlying)
Footnotes (6)
- [F1]The shares were sold to cover the $10 exercise price of the 6,483 vested stock options. The net shares of 883, after selling to cover the exercise price, will be held by the Reporting Person.
- [F2]This transaction was executed in multiple trades at prices ranging from $11.60 to $11.83. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]The shares were sold to cover the $10 exercise price of the 2,231 vested stock options. The net shares of 282, after selling to cover the exercise price, will be held by the Reporting Person.
- [F4]The shares were sold to cover the $10 exercise price of the 7,279 vested stock options. The net shares of 673, after selling to cover the exercise price, will be held by the Reporting Person.
- [F5]This transaction was executed in multiple trades at prices ranging from $11.00 to $11.30. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F6]On May 17, 2016, the reporting person was granted an option to purchase 35,000 shares of Common Stock. The options vest as follows: (i) 11,667 share upon the up listing of the Issuer to The NASDAQ Stock Market (which occurred on August 29, 2017); (ii) 11,667 shares upon the cumulative funding of the Issuer in excess of $5,000,000 by institutional investors, commencing May 5, 2016 (which performance criteria was met on December 13, 2016); and (iii) 11,666 shares upon the first submission of a New Drug Application ("NDA") to the FDA for one of Issuer's products by either the Issuer or an Issuer licensee.
Documents
Issuer
OPIANT PHARMACEUTICALS, INC.
CIK 0001385508
Entity typeother
Related Parties
1- filerCIK 0001685788
Filing Metadata
- Form type
- 4
- Filed
- Mar 16, 8:00 PM ET
- Accepted
- Mar 17, 4:53 PM ET
- Size
- 19.9 KB